Abstract. Although Bmi1 is well established as one of the most commonly activated oncogenes, the precise role of Bmi1 during hepatocarcinogenesis remains unclear. In addition, Bmi1 provides a potential therapeutic target for the future treatment of hepatocellular carcinoma (HCC). In this study, the expression of Bmi1 in HCC tissues was evaluated by immunohistochemistry and western blot analysis. We found that Bmi1 was much more highly expressed in HCC tissue compared to normal liver tissue. The shRNA-mediated knockdown of Bmi1 was used to assess the effects of Bmi1 in hepatocarcinogenesis. Bmi1 downregulation reduced cell growth and tumorsphere formation in vitro. A cell cycle analysis using flow cytometry clarified that Bmi1 knockdown blocked the cell cycle transition from the G0/G1 to the S phase. Additionally, the Bmi1 knockdown led to reduced tumorigenicity in vivo. Furthermore, Bmi1 expression enhanced the sensitivity of HCC to the therapeutic agent, sorafenib. Taken together, the current results demonstrate that Bmi1 functions as a promoter in cell proliferation and hepatocarcinogenesis, providing a potential therapeutic target for the future treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of mortality worldwide; there are 600,000 estimated new HCC cases annually and almost as many as deaths (1) . This malignancy occurs more often in men than in women, with higher incidence rates reported in several areas of Asia and Africa.
Sorafenib is one of the FDA-approved molecular targeted drugs for advanced HCC, and it confers significantly improved survival. Despite such advances in HCC therapy, the poor prognosis of HCC is still unavoidable due to the rapidly dividing cells that are the primary targets of traditional anticancer therapy (2) . In the cancer stem cell (CSC) theory, only a limited number of cells within the tumor, which are termed CSCs, are proposed to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. CSCs have been identified and isolated from hematopoietic malignancies and other solid tumors, including glioblastoma, breast cancer, colon cancer and hepatocellular carcinoma (3) (4) (5) (6) (7) . Currently, there is no drug that specifically targets this fraction of tumor cells; therefore, CSC-targeted anticancer interventions are potential therapies for this malignancy.
The epigenetic regulator polycomb group (PcG) genes are thought to control cell fate, cell differentiation and cancer development. Bmi1 is one of the core components of the PcG protein complex, which is involved in axial patterning, hematopoiesis, cell proliferation and senescence (8) (9) (10) (11) . Bmi1 was first identified as an oncogene for the generation of B-or T-cell leukemia in cooperation with c-Myc, which is dysregulated in various human cancers, such as colorectal carcinoma, HCC and lung cancer (12) (13) (14) . Furthermore, Bmi1 as a stem cell gene has been defined by the fact that its deficiency leads to compromised adult stem cell function (15) . It has been demonstrated that Bmi1 is necessary for the maintenance of stemness in leukemic stem cells and solid tumor stem cells, including HCC cells (16) (17) (18) . Importantly, the overexpression of Bmi1 correlates with therapy failure in many tumor types, including those in breast, prostate, lung and ovarian cancer patients (14, 19, 20) .
In the present study, we performed detailed analyses to examine the roles of Bmi1 in HCC. Bmi1 expression was evalu ated by western blot analysis and immunohistochemical staining in normal liver and HCC tissues. Bmi1 knockdown in the HCC cell lines inhibited tumorsphere formation in vitro and cell growth and tumor formation in vivo. A cell cycle analysis clarified that the knockdown of Bmi1 induced cell cycle arrest. Furthermore, Bmi1 knockdown also enhanced the sensitivity of HCC to the therapeutic agent, sorafenib.
Materials and methods
Patients and clinicopathological analysis. Surgical resection samples were obtained from 47 patients (including 9 females and 38 males) diagnosed with HCC at the First Affiliated (4) . The intensity of staining was also divided into 4 ranks of scores: no staining (1), light brown (2), brown (3) and dark brown (4) . The positivity of Bmi1 staining was determined by the following formula: immunohistochemistry score = percentage score x intensity score. An overall score of ≤8 was defined as negative and >8 as positive.
Bmi1 knockdown inhibits hepatocarcinogenesis
Cells and cell culture. The HCC-derived cell lines, Bel-7402 (CCTCC GDC035), SMMC-7721 (CCTCC GDC064) and HepG2 (CCTCC GDC024), were all purchased from the China Center for Type Culture Collection (CCTCC; Wuhan, China). The cells were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) in a humidified atmosphere at 37˚C with 5% CO 2 . The MHCC97 cells (Cell Bank of Chung Shan Hospital, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% FBS in a humidified atmosphere at 37˚C with 5% CO 2 .
Bmi1 shRNA vector construction and transfection. The oligonucleotide insert for the hairpin siRNA targeting the Bmi1 mRNA sequences was GGAGGAACCTTTAAAGGA TTA. The oligonucleotide sequences were 5'-CACCGGAG GAACCTTTAAAGGATTATTCAAGAGATAATCCTTTAA AGGTTCCTCCTTTTTTG-3' and 5'-GATCCAAAAAAGG AGGAACCTTTAAAGGATTATCTCTTGAATAATCCTTT AAAGGTTCCTCC-3'. The synthesized oligonucleotide (GenePharma, Shanghai, China) inserts were annealed and cloned into the PGPU6/GFP/neo-shRNA expression vector (GenePharma) to generate PGPU6/GFP/neo-shBmi1. The plasmid PGPU6/GFP/neo-shControl (GenePharma) was used as the negative control and encoded a hairpin siRNA with a nonsense sequence.
For stable cell line generation, the transfection was performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. Bmi1 stable-knockdown cells and the control cells were selected using 0.8 mg/ml G418 (Calbiochem, La Jolla, CA, USA).
Western blot analysis. Western blot analyses were performed as previously described using cell lysates (21). The crude proteins were then subjected to SDS-PAGE and then transferred onto a PVDF membrane. After blocking, the membrane was incubated with the appropriate antibody against Bmi1 (Millipore) or β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4˚C overnight, followed by a horseradish peroxidase-labeled secondary antibody. The blots were developed using a chemiluminescent detection system (Amersham Life Science, Buckinghamshire, UK).
Cell cycle assay. Cells (1x10 6 ) were cultured in 6-well plates for 24 h and then harvested and washed with PBS, followed by fixation with 70% ethanol overnight at 4˚C. After washing with PBS twice, the cells were stained in PBS with 50 µg/ml propidium iodide (PI; Sigma, St. Louis, MO, USA) and 10 µg/ml RNase A (Sigma) at room temperature in the dark. The cell cycle was assessed by flow cytometry (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA), and the data were analyzed with the FACSCalibur flow cytometer using ModFit LT software.
Cell proliferation and colony formation assay. Cell proliferation was evaluated on days 1, 3, 5, and 7 after seeding the cells (5x10 4 ) in triplicate in 6-well plates. A total of 200 cells plated on 100-mm cell culture dishes in triplicate were cultured for 3 weeks. The cell colonies were stained with Giemsa solution after being fixed in methanol for 15 min at room temperature.
Tumor xenografts. The stable Bmi1 knockdown or control cell line (10 6 cells) was injected into the subcutaneous tissue in the dorsum of 4-6-week-old male Balb/c-nude mice. Three animals per group were used in each experiment. The tumors were measured weekly using a vernier caliper, and the volume was calculated according to the following formula: length x width 2 /2. At the end of the experiment, the tumors were dissected, and their net weights were measured. The experimental protocols were evaluated and approved by the Animal Care and Use Committee of the Medical College of Xi'an Jiaotong University.
Drug experiments. Sorafenib was dissolved in DMSO (Sigma) and diluted with RPMI-1640 to the desired concentration (5 µM), with a final DMSO concentration of 0.1% for the in vitro studies. DMSO at 0.1% (v/v) was used as a solvent control.
Cells (1x10   3   ) were plated on 100-mm cell culture dishes in triplicate, and cultured for 3 weeks. Sorafenib or the solvent was added at the appropriate concentration after 24 h. The cell colonies were stained with Giemsa solution after being fixed in methanol for 15 min at room temperature.
A total of 5,000 cells were inoculated in 96-well microtiter plates and incubated overnight at 37˚C in a humidified incubator with 5% CO 2 . The cell viability was quantified every day using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) staining, according to a standard protocol. The cells were incubated with sorafenib at various concentrations for an additional 72 h to evaluate the inhibitory effect of sorafenib on cell proliferation. The number of viable cells was determined by measuring the absorbance at 490 nm.
Statistical analysis.
All the experiments were repeated at least in triplicate. The data from all of the experiments were pooled, and the results are expressed as the means ± SD. The statistical analysis was performed using SPSS 16.0 software (SPSS Inc.; Chicago, IL, USA). The two-tailed χ 2 test was used to determine the significance of the differences between the co-variates. For 2-group analyses, Student's t-test was used to determine the statistical significance, whereas Pearson's linear regression analysis was performed to examine the correlation between 2 quantitative variables. P<0.05 was considered to indicate a statistically significant difference.
Results

Bmi1 expression in human HCC tissues and cell lines.
To evaluate Bmi1 expression, western blot analysis was performed using 9 pairs of HCC tissues and their corresponding adjacent non-tumor tissues. Bmi1 expression was normalized to β-actin expression for the semi-quantification analyses. As shown in Fig. 1A and B, Bmi1 expression was significantly higher in all 9 of the cancer tissues than in the matched nontumor tissues (P<0.001). Furthermore, to determine whether Bmi1 overexpression was linked to the clinical progression of HCC, 47 HCC tissues and 10 normal hepatic tissues were characterized for Bmi1 expression by immunohistochemistry. However, none of the 10 normal tissues were found to be positive for Bmi1, whereas Bmi1 expression was detected in 17 of the 47 cases of HCC (36.17%) (Fig. 1C) . In addition, there was no significant correlation between Bmi1 expression and clinicopathological features (Table I ). Bmi1 expression in 4 HCC cell lines was detected using western blot analysis (Fig. 1D ). Bmi1 showed a high level of expression in the HepG2 and MHCC97 cell lines. Taken together, the western 
Bmi1 knockdown inhibits the proliferation and tumorsphere formation of HCC cells.
To explore the role of Bmi1 in the development of HCC, we introduced shRNAs to suppress Bmi1 gene expression in HepG2 and MHCC97 cells (Fig. 2A) ; we also wished to examine how Bmi1 modulates the proliferation of HCC cells. The HepG2 and MHCC97 cells in which Bmi1 was knocked down (HepG2-shBmi1 and MHCC97-shBmi1) presented significantly lower proliferation rates than the HepG2-shControl and MHCC97-shControl cells. These results showed that the knockdown of Bmi1 expression significantly inhibited the in vitro proliferation of HCC cells (Fig. 2B) . The clone formation assay showed that the Bmi1 knockdown cells formed fewer clones on the plates than the controls (P<0.05) (Fig. 2C and D) , suggesting that the knockdown of Bmi1 expression significantly inhibited the in vitro proliferation of HCC cells. Recently, a number of studies have indicated the existence of CSCs in HCC, cells that are critical for the maintenance of tumor growth, progression and metastasis (22, 23) . It has been demonstrated that Bmi1 regulates the proliferation and differentiation of CSCs in other types of cancer in addition to HCC stem cell formation. We used a tumorsphere culture system to investigate the potential role of Bmi1 in tumorsphere formation. 
Bmi1 knockdown blocks the cell cycle transition from the G0/ G1 to the S phase.
To determine whether Bmi1 is involved in the abnormal proliferation of HCC, we examined PCNA staining in HCC pathological specimens. The PCNA labeling index (PCNA-LI) was the cell proliferation index, and we examined the correlation between Bmi1 staining and cell proliferation activity in HCC tissues. The results showed increased cell proliferation activity in the tissues with higher Bmi1 expression (32.76±4.75 vs. 28.97±3.71%, Fig. 1A and B) . Changes in cell proliferation are typically associated with cell cycle modulation, and Bmi1 has been reported to promote the proliferation of a cervical cancer cell line by accelerating the cell cycle. To investigate the mechanisms by which Bmi1 regulates HCC cell proliferation, the cell cycle was investigated using flow cytometry after Bmi1 knockdown using shRNA. As shown in Fig. 3C , the percentage of HepG2-shControl cells in the G0/G1 phase was significantly greater (71.52%) than that of HepG2-shBmi1 cells (67.34%). A similar trend was observed for the MHCC97-shControl cells (66.95%) and MHCC97-shBmi1 cells (56.63%), suggesting that the Bmi1 knockdown led to cell cycle arrest (Fig. 3D) . Furthermore, there were no significant differences in cell apoptosis between the HepG2-shBmi1-and HepG2-control-transfected cells (data not shown), indicating that silencing Bmi1 inhibited tumorigenicity and was a result of the arrested cell cycle transition and not cell apoptosis.
Bmi1 knockdown inhibits the tumor formation of HCC cells in vivo.
To validate the role of Bmi1 in tumor formation in vivo further, xenograft assays were performed by injecting Bmi1-silenced HCC cells and control cells into nude mice. Although the HepG2-shControl and HepG2-shBmi1 cells induced palpable tumors by 8 weeks after the injection, the HepG2-shBmi1 cells developed smaller tumors, with an average size of 678 mm 3 and an average net weight of 0.77 g, than those derived from the HepG2-shControl cells (1,492 mm 3 /1.24 g, Fig. 4A-C) . Similar data were obtained from the MHCC97-shControl and MHCC97-shBmi1 cells. Collectively, these data demonstrate that the knockdown of Bmi1 inhibits cell proliferation and tumorigenicity in vivo.
We then examined the expression of the Bmi1 and Ki67 proteins by immunohistochemistry in all the xenograft tumor tissues formed by the HepG2-shControl, HepG2-shBmi1, MHCC97-shControl and MHCC97-shBmi1 cells (Fig. 4D) . The tumor tissues formed by HepG2-shBmi1 expressed lower levels of Ki67 and Bmi1 than those formed by the HepG2-shControl cells (Fig. 4E) . Similar results were obtained for the MHCC97-shControl and MHCC97-shBmi1 cells. These results demonstrate that Bmi1 promotes tumor formation and the development of HCC through accelerated cell proliferation.
Bmi1 knockdown enhances the sensitivity of human HCC cells to sorafenib. Sorafenib is currently the most promising molecular targeted drug for human HCC. To investigate whether Bmi1 affects the sensitivity of HCC cells to sorafenib, we treated HepG2-shBmi1 cells and HepG2-shControl cells with sorafenib at various concentrations. In this figure, the results display the effects of sorafenib at a concentration of 5 µM. As shown in Fig. 5A and B, the number of colonies formed by the HepG2-shBmi1 cells was lower than that formed by the HepG2-shControl cells. In addition to forming the least number of colonies, the HepG2-shBmi1 cells, with or without sorafenib, all showed a significantly lower proliferation rate than the control cells throughout the experimental period, as measured by cell viability assay (MTT assay) (P<0.05; Fig. 5C ). We also observed that patients (n=47) who showed negative Bmi1 expression had longer survival times, as revealed by a Kaplan-Meier analysis (P<0.05; Fig. 5D ).
Discussion
Bmi1 is widely expressed in a variety of human tumors, including medullo blastomas (24) , non-small cell lung (25) , breast (26) , prostate (27) and bladder cancer (28) . Microarray analyses of multiple types of cancer have also indicated that Bmi1 is a predictor of metastasis and poor survival (29) . In this study, we examined the expression of Bmi1 in HCC, non-tumor liver tissues and normal liver tissues, and observed that Bmi1 was overexpressed in HCC. To determine the role of Bmi1 in the growth of HCC, we established stable Bmi1-knockdown cells in the HepG2 and MHCC97 cell lines by inducing the expression of an shRNA that targeted Bmi1-specific mRNA in Balb/c-nude mice. We found that the knockdown of Bmi1 expression inhibited cell growth and colony formation by inducing cell cycle arrest in the G0/G1 phase. We also observed that the knockdown of Bmi1 expression attenuated the development and growth of the implanted HCC cells. These observations demonsrtate that Bmi1 promotes HCC cell tumor formation by accelerating cell growth. Our results are in agreement with those from previous reports showing that Bmi1 knockdown inhibits cell growth and reduces metastasis in various types of cancer (17, 30, 31) .
Ample evidence exists demonstrating the correlation between Bmi1 expression and the self-renewal and pluripotency maintenance of both normal and CSCs (18,32,33 ). Bmi1 has been reported to be highly expressed in CD133 + murine liver CSCs and to play a role in the maintenance of hepatic stem progenitor cells (18) . This finding is of great interest as the knockdown of Bmi1 expression decreases the tumorsphere formation ability under the sphere culture condition that allows the proliferation of only CSCs and progenitor cells. Previous studies have shown that Bmi1 controls self-renewal and the cell cycle by regulating the tumor suppressor proteins, p16INK4a and p14ARF, in cells (34, 35) . In the present study, we found that Bmi1 knockdown induced cell cycle arrest at the cellular level. Therefore, Bmi1 may regulate the growth of HCC by promoting the proliferation of both CSCs and cancer cells. Furthermore, it would be of interest to examine the reliable surface markers of HCC CSCs and to investigate the role of Bmi1 in the proliferation and differentiation of HCC CSCs.
To date, sorafenib is the first and only drug that has been shown to be beneficial for the overall survival of patients with HCC. Preclinical studies have shown that sorafenib potently decreases HCC proliferation. Animal studies as well as clinical trials have shown that the co-administration of therapeutic agents should be more beneficial than monotherapies (36, 37) . Experiments in vivo and in vitro have clearly esta blished that Bmi1 is an oncogene that plays critical roles in promoting CSC self-renewal and tumorigenesis in HCC. We also assessed the sensitivity of HepG2-shBmi1 and MHCC97-shBmi1 cells to sorafenib in terms of their proliferation. We demonstrated that sorafenib had a more potent inhibitory effect on shBmi1 cell proliferation than that of the shControl cells. These results demonstrate that reduced Bmi1 protein levels inhibit hepatocarcinogenesis by targeting CSCs and providing a potential therapeutic target for the future treatment of HCC.
In conclusion, the results from our study showed that Bmi1 was overexpressed in HCC compared with the adjacent non-tumor tissues, as indicated by western blot analysis and immunohistochemical staining. The knockdown of Bmi1 in the HCC cell lines inhibited cell growth and colony formation by arresting the cell cycle in the G0/G1 phase. Additionally, tumorsphere formation, representing in vitro CSC selfrenewal, was also repressed. Furthermore, Bmi1 knockdown also enhanced the sensitivity of HCC cells to the chemotherapeutic agent sorafenib. These results support the idea that the suppression of Bim1 expression significantly inhibits hepatocarcinogenesis.
